Amy Emerson, CEO of Lykos Therapeutics, steps down | Where to buy CBD online

Learn how to buy CBD Oil online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Privately-owned Lykos Therapeutics Continues to reel from its devastating rejection The FDA has approved the MDMA drug of the company. The company announced the resignation of its Chief Executive Officer Amy Emerson will be stepping down She will transition to a senior adviser role until the end of the calendar year. She will also serve on the Lykos Board as an Observer.

Michael Mullette will be the interim CEO of Lykos. Mullette has been Chief operating officer (COO) at the company since early 2022. Mullette, who joined Lykos in 2012 after spending more than 20 years in the pharmaceutical industry and most recently heading up its Pharmaceutical Division, is the company’s interim CEO. North America Moderna, where he was responsible for the commercialization of COVID-19 vaccine at the height of pandemic.

“Mike is an experienced leader with the background and skills needed to guide Lykos in our engagement with the FDA, and as we work to bring this groundbreaking treatment to patients who need it,” said Jeff George, Chairman of Lykos’ Board of Directors. “Mike’s role as COO has been highly influential and he has a profound understanding of the road ahead. He brings with him a wealth and impressive track record of over two decades working in the pharmaceutical industry. He is well-equipped to guide Lykos into the future.

In addition to Mullette’s appointment, Dr. David Hough, who was announced as Lykos senior medical advisor recently, officially joins the company in his new role as Chief Medical officer. Dr. Hough continues to oversee Lykos’ clinical development program, and its regulatory engagement with FDA regarding the resubmission midomafetamine. Lykos informed the marketplace that Dr. Hough spent 17 years at Johnson & Johnson where he was responsible for the Spravato Phase 3 development, approval and multiple markets of Spravato.

Emerson She was CEO of Lykos for almost 10 years. She began working on the midomafetamine project in 2003, and was appointed as CEO of Lykos (then MAPS PBC), upon its formation in 2014

“We founded Lykos because we believed in the need for mental health innovation, and I’m deeply grateful for the opportunity to lead our efforts,” said Emerson. “While we’re not at the finish, the last decade has seen a lot of progress. Mike has been a great partner and is ready to take the next step. “I know he’ll continue to pursue Lykos mission of helping patients unwaveringly and with resolve.”

Restructuring

Last month, Green Market Report Write that Lykos Therapeutics After the federal government rejected its application for a drug based on MDMA that was intended to treat post-traumatic disorder, the company announced a reorganization. The company assured stakeholders that it would not give up. It reduced its staff by about 75%. Those who remained focused their efforts on getting FDA approval of the MDMA capsules.

The final part of the reorganization was the departure of Dr. Rick Doblin from the board of directors of Lykos. He is the founder of Multidisciplinary Association for Psychedelic Studies.